CJC-1295 research guide for Fardīs. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Fardīs trying to locate CJC-1295, the key fact to understand is that this compound moves through online research channels. This matters because CJC-1295 quality differs enormously across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor controls every quality variable. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. Use this guide to assess sourcing options methodically — the quality evaluation approach outlined here apply whether you are in Fardīs or anywhere else.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Fardīs researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor share complete COA data without being asked? Suppliers that publish proactively are signalling genuine quality commitment. The HPLC analytical chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be 98% or higher. Strong quality indicators beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Fardīs
COA-verified · International tracking · Research grade
All use of CJC-1295 in Fardīs or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by aliquoting into single-use portions. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Protocol documentation — documenting product details, dates, and administration precisely — is a fundamental research principle that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
